{"analyses":[{"ciLowerLimit":"0.428","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.727","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.56","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"14.8","value":"13.4"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"10.0","value":"8.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days","title":"Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation","type":"SECONDARY","unitOfMeasure":"Months"}